Retinopathy of prematurity in surfactant treated infants.
Seventy six babies of less than 1500 g birth weight who had surfactant replacement therapy for severe respiratory distress syndrome were studied to assess the presence and stage of subsequent retinopathy of prematurity (ROP). A control group of 90 babies, matched for birth weight and gestational age, who did not have surfactant therapy were also studied. Threshold ROP or greater was found in 1.7% of the surfactant group and 7.8% of the controls. For the babies of less than 1000 g birth weight 4.0% of the surfactant babies and 16.3% of the controls reached threshold disease or greater. It is concluded that surfactant therapy is not associated with an increased incidence or severity of severe ROP in this preterm population.
Rankin
S J
SJ
Ophthalmology Department, Royal Victoria Hospital, Belfast, Northern Ireland.
Tubman
T R
TR
Halliday
H L
HL
Johnston
S S
SS
D001688:Biological Products; D001724:Birth Weight; D005260:Female; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D010743:Phospholipids; D011663:Pulmonary Surfactants / Q000009:adverse effects*; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy; D012178:Retinopathy of Prematurity / Q000139:chemically induced*
D001688:Biological Products; D010743:Phospholipids; D011663:Pulmonary Surfactants; C068291:poractant alfa